Park Byeong Geun, Seul Tae Woong, Shin Jung Jin, Son Sang Wook
Department of Dermatology, Korea University Ansan Hospital, Ansan, Korea.
Ann Dermatol. 2023 Dec;35(6):417-423. doi: 10.5021/ad.22.223.
Atopic dermatitis (AD) is a common skin disease which, depending on its severity, can have a significant impact on the quality of life of affected individuals. In cases of severe AD, systemic immunomodulatory agents can be considered for treatment. However, the available treatment options for moderate AD are limited. According to previous reports, however, 308-nm excimer light is a potential treatment for localized, moderate AD.
This study aimed to assess the clinical efficacy and safety of 308-nm excimer light in Korean adults with AD.
This study included Korean patients aged over 19 years, who were diagnosed with AD by a dermatologist, with bilateral, symmetric, and eczematous lesions. The symmetrical lesions in each patient were treated as control-test pairs. Treatment with 308-nm excimer light was applied to the test lesion twice a week for 4 weeks. The severity of the eczema, trans-epidermal water loss, and epidermal capacitance were measured.
A total of 25 participants were enrolled in the study. After the first visit, two participants withdrew, whereas the remaining 23 completed the study. There was a statistically significant improvement in AD severity in the test group than in the control group (<0.001). Skin barrier function also improved in the test than in the control group (<0.01).
This study provides preliminary evidence for the use of 308-nm excimer light as a treatment option to improve symptoms and skin barrier function in moderately localized AD.
特应性皮炎(AD)是一种常见的皮肤病,根据其严重程度,可对受影响个体的生活质量产生重大影响。对于重度AD病例,可考虑使用全身免疫调节剂进行治疗。然而,中度AD的现有治疗选择有限。然而,根据先前的报告,308纳米准分子光可作为局限性中度AD的一种潜在治疗方法。
本研究旨在评估308纳米准分子光对韩国成年AD患者的临床疗效和安全性。
本研究纳入了年龄超过19岁的韩国患者,这些患者由皮肤科医生诊断为AD,患有双侧、对称的湿疹样皮损。将每位患者的对称皮损作为对照-试验组。对试验皮损每周进行2次308纳米准分子光治疗,共治疗4周。测量湿疹的严重程度、经表皮水分流失和表皮电容。
共有25名参与者纳入本研究。首次就诊后,2名参与者退出,其余23名完成了研究。试验组AD严重程度的改善在统计学上显著优于对照组(<0.001)。试验组的皮肤屏障功能也比对照组有所改善(<0.01)。
本研究为使用308纳米准分子光作为改善中度局限性AD症状和皮肤屏障功能的一种治疗选择提供了初步证据。